Fetal nasal-bone examination could improve accuracy of Down's syndrome screening

November 15, 2001

N.B. Please note that if you are outside North America the embargo for Lancet Press material is 0001 hours UK time Friday 16th November 2001.

A new screening tecnique using ultrasonography to determine the presence or absence of nasal bone in fetuses aged 11-14 weeks could improve the accuracy of Down's syndrome screening, conclude authors of a fast-track study in this week's issue of THE LANCET.

Prenatal diagnosis of Down's syndrome (the identification of three copies of chromosome 21 in the fetus, also known as trisomy 21) requires an invasive test in women regarded as being at high risk after screening. Four screening methods are currently used, which have varying degrees of efficiency (sensitivity): maternal age alone (30% sensitivity); maternal age + maternal blood-testing in the second trimester of pregnancy (60-70%); maternal age + first-trimester fetal nuchal translucency scanning (75%); and maternal age + fetal nuchal translucency + maternal-blood analysis at 11-14 weeks (85%). The lack of efficiency of screening sometimes results in 'false-positive testing', resulting in the unnecessary use of invasive testing for some women with non-trisomy-21 fetuses; false-positive frequency from screening is around 1-5%.

Kypros Nicolaides and colleagues from the Harris Birthright Research Centre for Fetal Medicine, Kings College Hospital School of Medicine, London, UK, did an ultrasound examination of the fetal profile in 701 fetuses at 11-14 weeks' pregnancy. This was done immediately before karyotyping for a possible chromosomal abnormality detected by maternal age and fetal nuchal translucency screening. The presence or absence of a nasal bone was noted.

The nasal bone was absent in 43 of 59 (73%) trisomy 21 fetuses and in three of 603 (0.5%) chromosomally normal fetuses. Fetuses without a nasal bone were estimated to be at around 150 times more likely of having trisomy 21 compared with normal fetuses.

Kypros Nicolaides comments: " Our study suggests that examination of the fetal profile at 11-14 weeks could have major beneficial implications in screening for trisomy 21 by maternal age and fetal nuchal translucency. The increase in sensitivity from 75% to 85% could be achieved with a simultaneous reduction in the false-positive rate from 5% to about 1% and a consequent five-fold reduction in the rate of miscarriage from invasive testing and the cost of invasive testing and analysis."

In an accompanying Commentary (p 1658), Howard Cuckle from the University of Leeds, UK, concludes: "First-trimester screening has obvious benefits over second-trimester screening other than efficiency. These advantages include, for some, an early diagnosis with consequent safer and less traumatic therapeutic abortion, and, for most, an earlier reassurance...so where does this leave the UK Department of Health's forthcoming National Down's Syndrome Screening Programme? Despite a large body of published data on first-trimester markers and growing clinical experience with nuchal translucency, it is being planned as a second- trimester service. The findings on the nasal bone published today demand an urgent rethink of this policy."
-end-
Contact: Professor Kypros Nicolaides, Harris Birthright Research Centre for Fetal Medicine, King's College Hospital Medical School, Denmark Hill, London SE5 8RX, UK; T) +44 (0)20 7346 3040; E) fmf@fetalmedicine.com

Professor Howard S Cuckle, Reproductive Epidemiology, Centre for Reproductive Growth and Development, 26 Clarendon Road, Leeds LS2 9NZ, UK; T) +44 (0)113 233 6771; F) +44 (0)113 233 6774; E) h.s.cuckle@leeds.ac.uk

Lancet

Related Trisomy Articles from Brightsurf:

Plant compound reduces cognitive deficits in mouse model of Down syndrome
The plant compound apigenin improved the cognitive and memory deficits usually seen in a mouse model of Down syndrome, according to a study by researchers at the National Institutes of Health and other institutions.

Low risk of COVID-19 infection found among people with congenital heart disease
Results of a retrospective analysis suggest that people born with a heart defect who developed COVID-19 symptoms had a low risk of moderate or severe COVID-19 infection, according to a new article published today in the Journal of the American Heart Association, an open access journal of the American Heart Association.

New insights into why people with down syndrome are at higher risk for leukemia
Scientists from Stanley Manne Children's Research Institute at Ann & Robert H.

Research story tip: Down syndrome mice open door to better understanding of the disorder
Johns Hopkins Medicine researchers and their collaborators have created and characterized a new mouse replica of Down syndrome, long considered one of the most challenging disorders to simulate in laboratory animals.

Genes related to down syndrome abnormalities may protect against solid tumors
Scientists from Stanley Manne Children's Research Institute at Ann & Robert H.

New therapeutic targets for treating memory impairment in Down syndrome
Researchers from Hospital del Mar Medical Research Institute studied the neural basis of intellectual disability in mice with Down syndrome and discovered that the neural networks of brain circuits relevant to memory and learning are over-activated and that the connectivity of these circuits is poor.

Major discovery in the genetics of Down syndrome
New research highlights the RCAN1 gene's effect on memory and learning.

Research supports expanding insurance coverage of non-invasive prenatal testing
Research conducted by the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences provides evidence to support expansion of insurance plan coverage of noninvasive prenatal testing (NIPT), a simple maternal blood draw which screens for fetal chromosomal disorders including trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome), and trisomy 21 (Down syndrome), to women under the age of 35.

Exploring the risk of ALL in children with Down syndrome
Researchers discovered new clues that provide a better understanding of why children with Down syndrome have an increased risk of leukemia.

Advanced data analysis enhances precision medicine application in clinics
Scientists have published a novel computational framework for highly accurate and targeted Non-Invasive Prenatal genetic Testing (NIPT) assay, which enables the application of cost-effective TAC-seq laboratory method in clinical practice.

Read More: Trisomy News and Trisomy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.